For brand Adempas - Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name Adempas originating from Europe is manufactured at the following site(s):Bayer AG Kaiser-Wilhelm-Allee 51368 Leverkusen Germany
Information about ADEMPAS:
Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4), after surgery are prescribed Adempas (Riociguat) to improve their exercise ability and WHO functional class.
Additionally, it is indicated for improving exercise capacity, WHO functional class, and delaying clinical deterioration in adults with pulmonary arterial hypertension (PAH), WHO Group 1, either as monotherapy or in combination with endothelin receptor antagonists or prostanoids.
Product Highlights
Studies included patients with WHO functional class II–III.
Effective in idiopathic or heritable PAH (61%) and PAH associated with connective tissue diseases (25%).
Stimulates soluble guanylate cyclase (sGC) leading to increased levels of cyclic guanosine monophosphate (cGMP), resulting in vasodilation.
Requires careful monitoring due to potential for hypotension, particularly in combination with vasodilators.
Key Ingredients
Riociguat
Cellulose microcrystalline
Crospovidone, hypromellose 5cP
Key Benefits
Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group 4, after surgical treatment, or inoperable CTEPH.
Treatment of adults with pulmonary arterial hypertension (PAH), WHO Group 1.
Improves exercise capacity.
Improves WHO functional class.
Delays clinical worsening in PAH.
Direction For Use
Dosage
Administration Schedule
Starting Dose
1 mg three times a day
Alternative Starting Dose (if hypotension risk)
0.5 mg three times a day
Titration
Increase by 0.5 mg three times a day, if systolic BP > 95 mmHg and no hypotension symptoms, every 2 weeks
Maximum Dose
Up to 2.5 mg three times a day (highest tolerated dosage)
Adjustment for Hypotension
Decrease by 0.5 mg three times a day, if hypotension symptoms occur
Packaging
color
Debossing Side 2
NDC 50419-xxx-xx
Bottle of 9
Bottle of 9
Bottle of 9
0.5 mg
White
0.5 R
250-91
250-1
250-3
1 mg
Pale yellow
1 R
251-91
251-1
251-3
1.5 mg
Yellow-orange
1.5 R
252-91
252-1
252-3
2 mg
Pale orange
2 R
253-91
253-1
253-3
2.5 mg
Red-orange
2.5 R
254-91
254-1
254-3
Safety Concern
Adempas and all medications should be kept out of children's reach.
Adempas should not be used more than 7.5 mg in a single day unless prescribed by a physician.
Remind patients that using Adempas in combination with nitrates, nitric oxide donors, or PDE-5 inhibitors is contraindicated.
Inform patients of the possible dangers and symptoms of hemoptysis, and urge them to notify their doctors of any suspected symptoms.
Avoid Taking if ADEMPAS:
Women who are pregnant or intend to become pregnant should not take Adempas.
